Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ultra-low dose IL2 (Proleukin) in children and adolescents with type 1 diabetes

The purpose of this trial is to assess the safety, tolerability and optimal dose of Proleukin in children and adolescents with type 1 diabetes, through study of the effects on the immune system and metabolic parameters. Note this trial was originally called DILTY